Rhumbline Advisers Cassava Sciences Inc Transaction History

Rhumbline Advisers

$113 Billion
Q2 2025

A detailed history of Rhumbline Advisers transactions in Cassava Sciences Inc stock. As of the latest transaction made, Rhumbline Advisers holds 1,734 shares of SAVA stock, worth $6,901. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,734

Previous 58,958 97.06%

Holding current value

$6,901

Previous $88,000 96.59%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	SELL	$1.19 - $2.24 $68,096 - $128,181	-57,224 Reduced 97.06%	1,734 $3,000
Q1 2025 Apr 08, 2025	BUY	$1.5 - $3.02 $1,693 - $3,409	1,129 Added 1.95%	58,958 $97,000
Q4 2024 May 29, 2025	SELL	$2.29 - $32.18 $2,585 - $36,331	-1,129 Reduced 1.91%	57,829 $136,000
Q4 2024 Jan 30, 2025	BUY	$2.29 - $32.18 $3,828 - $53,804	1,672 Added 2.98%	57,829 $136,000
Q3 2024 Nov 12, 2024	SELL	$9.57 - $35.08 $29,686 - $108,818	-3,102 Reduced 5.23%	56,157 $1.65 Million
Q2 2024 Aug 01, 2024	BUY	$12.35 - $26.11 $28,676 - $60,627	2,322 Added 4.08%	59,259 $731,000
Q1 2024 May 09, 2024	BUY	$18.44 - $26.41 $15,397 - $22,052	835 Added 1.49%	56,937 $1.16 Million
Q4 2023 Feb 08, 2024	SELL	$12.64 - $30.11 $8,178 - $19,481	-647 Reduced 1.14%	56,102 $1.26 Million
Q3 2023 Nov 09, 2023	SELL	$16.64 - $25.32 $4,193 - $6,380	-252 Reduced 0.44%	56,749 $944,000
Q2 2023 Aug 08, 2023	BUY	$21.59 - $27.88 $96,032 - $124,010	4,448 Added 8.46%	57,001 $1.4 Million
Q1 2023 May 11, 2023	BUY	$23.46 - $36.44 $18,322 - $28,459	781 Added 1.51%	52,553 $1.27 Million
Q4 2022 Feb 14, 2023	BUY	$27.82 - $44.16 $10,154 - $16,118	365 Added 0.71%	51,772 $1.53 Million
Q3 2022 Nov 10, 2022	BUY	$16.33 - $51.06 $75,526 - $236,152	4,625 Added 9.89%	51,407 $2.15 Million
Q2 2022 Aug 11, 2022	BUY	$17.22 - $38.47 $97,086 - $216,893	5,638 Added 13.7%	46,782 $1.32 Million
Q1 2022 May 12, 2022	BUY	$32.6 - $53.05 $72,698 - $118,301	2,230 Added 5.73%	41,144 $1.53 Million
Q4 2021 Feb 10, 2022	SELL	$36.77 - $90.91 $56,294 - $139,183	-1,531 Reduced 3.79%	38,914 $1.7 Million
Q3 2021 Nov 12, 2021	BUY	$41.79 - $135.3 $26,870 - $86,997	643 Added 1.62%	40,445 $2.51 Million
Q2 2021 Aug 05, 2021	SELL	$32.15 - $89.72 $181,197 - $505,661	-5,636 Reduced 12.4%	39,802 $3.4 Million
Q1 2021 May 06, 2021	BUY	$7.09 - $87.95 $81,166 - $1.01 Million	11,448 Added 33.68%	45,438 $2.04 Million
Q4 2020 Feb 10, 2021	BUY	$6.79 - $12.25 $74,988 - $135,289	11,044 Added 48.13%	33,990 $232,000
Q3 2020 Nov 12, 2020	BUY	$2.86 - $11.51 $2,639 - $10,623	923 Added 4.19%	22,946 $264,000
Q2 2020 Aug 13, 2020	BUY	$2.04 - $9.64 $44,926 - $212,301	22,023 New	22,023 $68,000

Others Institutions Holding SAVA

# of Institutions

131

Shares Held

14.2M

Call Options Held

962K

Put Options Held

864K

View Full List

About CASSAVA SCIENCES INC

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $160M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

More about SAVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Cassava Sciences Inc Transaction History